| Patient | Dwight D. Eisenhower |
|---|---|
| Date of birth | 1960-10-14 |
| Identifiers | MRN HR-ET015-SYN; SSN (made up) 000-15-2673 |
| Document date | 2026-09-28 |
| Author | Russell Okonkwo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
One-year review after myocardial infarction. [S]
Mr. Eisenhower returns one year after his myocardial infarction. He has had no chest pain, breathlessness, palpitations, or bleeding, and has not needed nitroglycerin. He works full time, travels, and plays golf twice a week. He did not get the basic metabolic panel ordered for July because he was travelling. He asks whether he can now stop ticagrelor, which bruises him, and whether he still needs metoprolol. [S]
| Element | Detail |
|---|---|
| Interval change | No angina, bleeding, or nitroglycerin use |
| Function | Full-time work, travel, and golf |
| Missed test | Basic metabolic panel due in July not drawn |
| Patient questions | Stopping ticagrelor and metoprolol |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Good energy; weight stable |
| Cardiovascular | Negative | No chest pain, palpitations, or edema |
| Respiratory | Negative | No breathlessness |
| Hematologic | Positive | Easy forearm bruising; no nosebleeds or other bleeding |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2025-09-24 | active | S |
| Ticagrelor 90 mg oral tablet, one tablet by mouth twice daily | One tablet by mouth twice daily | Oral route | 2025-09-24 to 2026-09-28 | completed | S |
| Atorvastatin 80 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2025-09-24 | active | S |
| Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2025-09-25 | active | S |
| Lisinopril 5 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2025-09-26 to 2026-01-12 | completed | S |
| Lisinopril 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 | active | S |
| Ezetimibe 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 | active | S |
| Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tablet | One tablet under the tongue every 5 minutes as needed for chest pain, up to 3 doses | Sublingual route | 2025-09-24 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-28 | Body height | 178 | cm | S |
| 2026-09-28 | Body weight | 77 | kg | S |
| 2026-09-28 | Body mass index (BMI) [Ratio] | 24.3 | kg/m2 | S |
| 2026-09-28 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-09-28 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-09-28 | Heart rate | 60 | /min | S |
| 2026-09-28 | Respiratory rate | 14 | /min | S |
| 2026-09-28 | Body temperature | 36.6 | Cel | S |
| 2026-09-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-28 | Cholesterol [Mass/volume] in Serum or Plasma | 116 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-09-28 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 45 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-09-28 | Triglyceride [Mass/volume] in Serum or Plasma | 110 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-09-28 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 49 | mg/dL | <=99 mg/dL | Normal | S |
| 2026-09-28 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-09-28 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-09-28 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-09-28 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 82 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-09-28 | Glucose [Mass/volume] in Serum or Plasma | 95 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-09-28 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 2026-09-28; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Skin | Small bruises on both forearms |
| Heart | Regular rhythm at 60; no murmur or gallop |
| Lungs | Clear |
| Extremities | No edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Anterior ST-elevation myocardial infarction about four months before intake, treated with a drug-eluting stent to the left anterior descending artery; synthetic modern episode linked to the documented 1955 anterolateral infarction | active | confirmed | I25.2 | S — Synthetic modern diagnosis; the 1955 infarction remains D in the history. |
| Coronary artery disease, single-vessel, after stenting; no angina | active | confirmed | I25.10 | S — Synthetic diagnosis supporting secondary prevention. |
| Hyperlipidemia, on high-intensity statin | active | confirmed | E78.5 | S — Synthetic diagnosis; no cholesterol value from his lifetime is used. |
| Essential hypertension | active | confirmed | I10 | S — Synthetic diagnosis; no blood pressure from his lifetime is used. |
| Former heavy cigarette smoker, quit about seven years before intake | active | confirmed | Z87.891 | S — Synthetic coded history echoing the documented heavy smoking and quitting around 1949. |
| Anterior epistaxis, right side, on dual antiplatelet therapy; controlled with silver nitrate cautery | resolved | confirmed | R04.0 | S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Dual antiplatelet therapy duration | At least 12 months after an acute coronary syndrome, then aspirin alone | Completed today | Twelve months completed without major bleeding; ticagrelor stopped today, aspirin continued |
| Medication safety | Beta-blocker review | Reassess one year after the infarction | Completed today | Continued for hypertension; LVEF 52 percent and no angina or arrhythmia |
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing therapy, then every 3 to 12 months | Completed today | LDL cholesterol 49 mg/dL on atorvastatin and ezetimibe, at goal |
| Laboratory | Basic metabolic panel | 1 to 2 weeks after starting or changing an ACE inhibitor, then every 6 months | Completed today | Potassium 4.5, creatinine 1.02 mg/dL, eGFR 82 |
| Laboratory | Basic metabolic panel six months after the last | Every 6 months on an ACE inhibitor | Deferred | Due in July and ordered at the last visit, but not drawn while he was travelling: a deviation from the protocol. Today's potassium and kidney function are normal, so no harm resulted. Corrective action: a laboratory reminder is now set for each six-month draw |
| Examination | Blood pressure, heart rate, weight and BMI, heart and lungs, edema | Every visit | Completed today | Blood pressure 124/74 mmHg, heart rate 60, weight 77.0 kg |
| Survey | Depression screen (PHQ-2) | Every visit | Completed today | Score 0 |
| Self-management | Tobacco use | Every visit | Completed today | Abstinent |
| Medication safety | Influenza, COVID-19, and RSV vaccination | Yearly influenza; others on the CDC schedule | Completed today | RSV vaccine given today; influenza and COVID-19 vaccines planned at next month's wellness visit |
| Laboratory | HbA1c | Yearly diabetes screen with hypertension | Up to date | 5.6% in January; due in January |
Goal progress:
Immunizations given today: Respiratory syncytial virus vaccine, single dose [S]
Guideline basis: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (2025); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, acute myocardial infarction, ischemic heart disease, hyperlipidemia, and hypertension monographs (2026)
Follow-up: Annual wellness visit next month. Coronary review with a lipid panel and basic metabolic panel in about six months. Next scheduled visit 2026-10-19: initial annual wellness visit. [S]